Professor Pål Aukrust has together with senior scientist dr. Arne Yndestad and professor Bente Halvorsen received ERA-NET funding on cardiovascular diseases (ERA-CVD). All three scientists are affiliated Research Institute of Internal Medicine at the Division of Surgery, Inflammatory Medicine and Transplantation (“KIT”), Oslo University Hospital and Institute of Clinical Medicine, University of Oslo.
The funding, amounting to 2.4 mill NOK over a period of three years, is based on a collaborative project with professor Joachim Schultze, Bonn, Germany, professor Michael Sieweki, Marseille, France, and professor Erik A Biessen, Maastricht, The Netherlands, who is heading the consortium. The project named AtheroMacHete (Atherosclerosis Macrophage Heterogeneity study) will particular focus on intra plaque macrophage heterogeneity in patients with atherosclerotic disorders and experimental model systems.
Six research groups were awarded for their excellent papers published during the first half-year of 2017 during a ceremony on December 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.
Per Steinar Halvorsen, head of the "Clinical and experimental cardiovascular monitoring" research group at the Intervention Centre at the Division of Emergencies and Clinical Care, was appointed "Innovator of the Month" for the month of October by South-Eastern Norway Regional Health Authority (Helse Sør-Øst).
His work is presented in an article (in Norwegian) entitled "Pacemaker of the future", published on the home page of Helse Sør-Øst.
Welcome to the next Oslo University Hospital (OUH) research seminar entitled:
The challenges of discovering new antibiotics
Time: Monday, December 4th at 14:30–16:00
Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo
Speakers: Kirsten Skarstad, Magnar Bjørås and Pål Rongved.
The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at Oslo University Hospital and University of Oslo, is combining structural and biophysical approaches with cellular and animal studies to unravel how the neonatal Fc receptor (FcRn) acts as a key player in regulation of the long serum half-life of albumin and IgG antibodies. The research group has signed a strategic research agreement with Roche Diagnostics GmbH where the aim will be to gain an in-depth understanding on how FcRn is regulating transport of engineered IgG antibodies in different types of cells. The agreement is part of the Roche Postdoctoral Fellowship program.
Alicia Llorente, project group leader at the Department of Molecular Cell Biology in the research group headed by Kirsten Sandvig, has recently received a grant to participate in a project funded by the Horizon2020 action ERA-NET TRANSCAN-2. TRANSCAN-2 is a collaborative network of ministries, funding agencies and research councils that aims to align national/regional translational cancer research programmes.
Both The Norwegian Research Council and The Norwegian Cancer Society participate in TRANSCAN-2. The project is funded by the Third Joint Transnational Call (JTC 2016) dedicated to "Minimally and non-invasive methods for early detection and/or progression of cancer". A total of 14 projects were funded under this call, and three of them have Norwegian participants.
Dr. Anita Sveen from Ragnhild Lothe's group at the Department of Molecular Oncology received the Young Investigator prize at Onkologisk Forum for her research accomplishments. This annual meeting for oncologists took place in Oslo on November 16-17. The award amounts to 50.000 NOK, to be spent on research.
Sveen presented her research in computational oncology, focusing on clinical relevant questions for colorectal cancer and novel results published in 6 selected papers.
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".
For the month of October 2017, this honour went to Michael Bretthauer from the Department of Transplantation Medicine at the Division of Surgery, Inflammatory Diseases and Transplantation.
Cell-cycle checkpoints are crucial for the maintenance of genomic integrity. The checkpoint operating in G2 phase of the cell cycle prevents entry into mitosis in the face of DNA damage. In cancer cells checkpoints are often deficient and thus they most likely rely on alternative pathways.
The authors describe a novel pathway for delayed entry into mitosis in response to DNA damage, which does not depend on the classic checkpoint pathways. Instead, the pathway involves selective translation regulation of a key mitotic regulator, cyclin B. This work is the first demonstration of selective translation regulation of a cell-cycle regulator in response to DNA-damage stress and raises the question whether similar pathways also exist in cancer cells with impaired checkpoints.
The findings are selected for the "In this issue" section in "Journal of Cell Science" on Dec 1st.
The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, is studying the cellular processes and molecular interplay underlying the functions of the two most abundant proteins in blood, albumin and IgG. By combining structural and biophysical approaches with cellular and in vivo studies, they use the insights to design novel albumin and antibody molecules with improved functions. The research group has now received a grant of 8.5 million NOK from The research Council of Norway (NANO2021 program) to expand their work on how such engineered ligands can be explored in combination with nanoparticles for tailored mucosal delivery. The project is entitled “A novel nanoparticle-based approach for mucosal delivery of therapeutics".
There were 61 applicants, of which two (including this application) obtained the highest possible rate.
Taskén`s current position is Director of the Center for Molecular Medicine Norway – NCMM (merged with the Biotechnology center in 2017). He will begin in his position as Head of Department in January 2018.
Kjetil Taskén is 51 years old (born December 19, 1965), and he is a highly qualified and experienced research leader with very relevant background as head of a large unit for biomedical research (120-180 employees at NCMM).
Taskén is an active researcher who can be credited for a total of 269 publications, and well over 12,000 citations. He also holds an h-index of 59 within both basic research and translational research. In 2016, he was awarded the prestigious King Olavs Vs Cancer Research Prize for his work on immunotherapy, a field of expertise that Taskén has been involved in ever since he started his research in 1994. Furthermore, he also leads one of six research groups in the KG Jebsen Center for cancer Immunotherapy (led by Johanna Olweus).
The authors demonstrate the power of meta-analysis to identify rare somatic variants in cancer, and they identify several copy number alterations of potential importance for tumor development in those affected. The paper contributes to the understanding of the diversity of evolutionary processes in cancer.
The study, published online in Nature Communications on 31 October, is collaboration between OUS, UiO and several international partners. First author Jiqiu Cheng from the Hege Russnes group at the Department of Cancer Genetics at the Institute for Cancer Research. The senior author of the paper is Peter Van Loo at the Francis Crick Institute in UK.
Thomas Fleischer and Xavier Tekpli from the Cancer Genome Variation group, lead by Vessela Kristensen at the Department of Cancer Genetics, IKF, together with their collaborators from the NCMM, Toni Hurtado and Anthony Mathelier, and Professor Arnoldo Frigessi from UiO identified methylated regions (CpGs) that show remarkably and reproducibly conserved patterns of association to gene expression in the DNA from breast tumors in three independent breast cancer cohorts. These patterns result in two main signatures (clusters), one reflecting infiltrating immune cell signatures and another related to estrogen receptor signalling. These results indicate that, in at least some forms of cancer, aberrant DNA methylation occurs not as chaotic stochastic process but is precisely regulated.
The results were published online in Nature Communications November 9th .
Maria Torgersen, researcher in the group of Kirsten Sandvig in Department of Molecular Cell Biology, is presently working in NANOCAN, the national competence building project of nanomedicine including 10 research groups in Norway. Maria has now received a grant of 8.5 million NOK from The research Council of Norway (NANO2021 program) to continue her work with studies of the importance of autophagy in cellular responses to uptake of nanoparticles. The project is entitled “nanoAUTOPHAGY – health implications of nanoparticle-induced changes in autophagy”. The grant includes salary for 4 years for Maria and 3 years for a PhD student. There were 61 applicants, of which two (including Maria) obtained the highest possible rate.
Which factors increase the risk of cancer? What is the relative importance of heritable factors, the environment and randomness? Such questions often lead to discussions and speculations, which unfortunately tend to be imprecise. In a recent publication in Nature Communications, researchers Mats J. Stensrud and Morten Valberg from Oslo Centre for Biostatistics and Epidemiology (OCBE) use statistical methods to quantify the distribution of genetic cancer risk in a population. Their results show that genes have a major influence on the risk of cancer. For 15 common cancers, the inequality in genetic cancer risk is larger than the inequality in income in the USA.
Structural breakdown of epithelial architecture is a cardinal hallmark of carcinomas - the most common forms of cancer.
Our cells contain tumor suppressor genes that act as gate-keepers to prevent tumor growth. One such classical tumor suppressor, Liver Kinase B1 (LKB1), was identified as being responsible for the hereditary cancer predisposition syndrome, Peutz-Jeghers syndrome. It has later been shown to be mutated in other cancer types, such as lung cancer.
Reporting in the prestigeous journal Nature Cell Biology (IF 20,6), O´Farrell and colleagues now reports that intracellular endocytic trafficking of LKB1 is essential to curtail Lkb1 activity from going rogue. In a surprising twist, they show that LKB1 can act to promote carcinogenesis, a role normally possessed by oncogenes.
Update: PNAS has published a commentary article about the findings in their "Journal Club" section, where recently published papers selected by Academy members are highlighted.
As part of the Oslo Breast Cancer Consortium (OSBREAC), surgeons, oncologist and Scientists from OUS have participated in the analysis of genetic data from 275,000 women, of whom 146,000 had been diagnosed with breast cancer.
Seventy-two new genetic variants that contribute to the risk of developing breast cancer have been identified by a major international collaboration involving hundreds of researchers worldwide.
Of these variants, reported October 23rd in the journals Nature and Nature Genetics, 65 are common variants that predispose to breast cancer and a further seven predispose specifically to oestrogen-receptor negative breast cancer – the subset of cases that do not respond to hormonal therapies.
The findings are the result of work by the OncoArray Consortium, a huge endeavour involving 550 researchers from around 300 different institutions in six continents of which OSBREAC is a part of.
The Principle Investigator of the Norwegian part of the study is professor Vessela N. Kristensen from the Department of Cancer Genetics at the Institute for Cancer Research.
The studies are covered by world-wide media channels, such as CNN.
In a press release, the pharmaceutical company Albumedix (Copenhagen, Denmark) has announced that it has signed a strategic research agreement with Oslo University Hospital and University of Oslo. The three organisations will work together to improve understanding of the interaction between bioengineered albumin variants and the neonatal Fc receptor (FcRn).
The research agreement is a result of a long collaboration between Albumedix scientists and Jan Terje Andersen and Inger Sandlie from CIR (UiO) and Department of Immunology (OUH).
A protein kinase complex known as mTORC1 is known to control cell growth by upregulating anabolic processes and downregulating catabolism in response to growth factors and nutritional cues such as amino acids. Because mTORC1 signalling is an important driver of cancer development, we need to understand how this signalling is regulated.
mTORC1 signalling occurs from lysosome membranes and is regulated by the lipid kinase PIK3C3 and its catalytic product, phosphatidylinositol 3-phosphate (PI3P), but the mechanism has remained unknown. Now, postdoc Zhi Hong and her co-workers in Camilla Raiborg’s project group at the Department of Molecular Cell Biology at the Institute for Cancer Research have discovered that PIK3C3 and PI3P control mTORC1 activation by regulating lysosome positioning.
The Norwegian Cancer Society present research they support regularly, in a popular science form.
Olav Engebråten from the Department of Oncology at OUH has recently (October 10th) been interviewed about The NeoAva study he is leading - a clinical breast cancer study for patients with tumors more than 2.5 cm in diameter, where treatment with bevacizumab is involved - a substance (antibody) that binds and removes one of the factors (VEGF) excreted from the cancer cells that may stimulate the growth of blood vessels. The treatment can therefore prevent blood vessels from growing into the tumor tissue, and enhance the effect of the chemotherapy in the tumor.
|Previous news articles|
|Individualized cancer treatment OUH research seminar, Monday, October 9th 14:30|
|Induced pluripotent stem cell research featured on Norwegian national news broadcast|
|Tor Inge Tønnessen "Researcher of the Month" for September|
|Collaboration to identify novel biomarkers that can predict whether a patient will respond positively to pembrolizumab|
|Scientific opportunities in Europe Sept 29th - Information day about EMBL, EMBO and HSPF:|
|Jahre lecture Thursday September 14th|
|The Norwegian Cancer symposium 2017 on Precision Medicine Scandic Holmenkollen Park, December 4-6, 2017:|
|Anne-Lise Børresen-Dale appointed Commander of the Royal Norwegian St. Olavs Order|
|ERC Starting Grant 2017 to Kyrre Eeg Emblem|
|Tone Rustøen "Researcher of the Month" for July|
|Håvard Danielsen appointed "Scientist of the Month" by "Helse Sør-Øst" for June 2017|
|OUH scientists involved in sequencing study of osteosarcoma that has identified mutations in IGF signalling genes|
|Øyvind S. Bruland appointed "Innovator of the Month" by Helse Sør-Øst|
|Lars Tjelta Westlye appointed "Scientist of the Month" by "Helse Sør-Øst" for May 2017|
|Annuncement of research funding from South-East Norway regional health authority for 2018 Call for applications 2018|
|Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2016|
|Clinically important genetic heterogeneity in colorectal cancers with microsatellite instability|
|Per O. Seglen awarded King Olav V's cancer research prize for 2017|
|New mechanism for rare skin disorder discovered|
|Norwegian research with international impact Less expensive medicine results in treatment for more patients|
|The 2017 Excellent Research Awards to Kirsten Sandvig, Johannes Espolin Roksund Hov and Tor Paaske Utheim|
|Organ donation for abdominal and thoracic organs OUH research seminar, Monday, May 8th 14:30 - 16:00|
|Placing my research in an H2020 project Program Info - workshops held May 8-9th:|
|New insight into late effects after cancer treatment presented by the Norwegian Cancer Society|
|Immunotherapy for Cancer OUH research seminar, Tuesday, April 25th 10:00 - 15:45|
|Study on replication fork stability from Skarstad group published in Nucleic Acids Research|
|Innovation to Finance Research OUH research seminar, Monday, April 3rd 14:30|
|NORMENT researchers contribute to PLOS Medicine article on genetic assessment of age-associated Alzheimer's disease risk|
|The AACR-WICR Friend Lectureship presented to Anne-Lise Børresen-Dale|
|CanCell a new Centre of Excellence will reprogram cancer cells|
|Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology New group leader at the Institute for Cancer Research:|
|Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research King Olav V´s Cancer Research Prize to Per O. Seglen (07.03.2017 10:32)|
|Health after transplantation OUH research seminar, Monday, March 6th 14:30|
|Early signs of mental illness in the developing brain NORMENT study published in Nature Neuroscience:|
|Arne Klungland talks about embryo research Breakfast lecture in Oslo Wednesday March 1st:|
|Thon Awards seminars 2017 Invitation to seminar March 2nd 12:00|
|Critical article on doping and drug testing published in EMBO reports|
|Early phase drug development: From idea to concept OUH research seminar, Monday, February 6th 14:30|
|"Science" article from Johanna Olweus's group highlighted by editorial in New England Journal of Medicine|
|6th National Conference on Stroke Oslo Kongressenter, February 09-10 2017|
|Theis Tønnessen appointed "Scientist of the Month" by "Helse Sør-Øst" for January 2017|
|Sepsis: New definitions and future research OUH research seminar, Thursday, January 26th|
|Excellent Researcher Award and Early Career Award 2017 Announcement: Nominating outstanding scientists, closing date March 1st:|
|Antimicrobial resistance - how bad is the situation in the world of virus, fungus and mycoplasma? OUH research seminar, Monday, January 16th|
|Findings from Rusten group published in Nature on microenvironmental autophagy draw nationwide attention Updated: honoured with "Preview" article in Developmental Cell|
|Commentary article from Arne Klungland in Nature Methods on epitranscriptome analysis|
|Research funding from South-Eastern Norway Regional Health Authority for 2017|
|Educating future cancer researchers from Ullern high school|
|Novel cancer immunotherapy published in Cancer Research, with cover illustration|
|Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2016|
|Oslo University Hospital research seminar: Exercise and Brain Energy Monday, November 21st, 2016, at 14:30 16:10|
|Oslo University Hospital research seminar: The World of Immunology Thursday November 17th at 10:00-15:00|
|Oslo University Hospital researchers receive 77.3 mill NOK from the Norwegian Cancer Society Results of Open Call 2016:|
|Human lung macrophages are self-maintained for several years|
|Announcement of research funding from the Norwegian Cancer Society Gathering Friday October 28th 10-12 at UiO:|
|Dag Berild awarded the "Akademikerprisen" for his work on antibiotic resistance|
|50 years anniversary Institute for Surgical Research Thursday 13 October 2016 at 10.15 AM|
|Making therapeutic antibodies from scratch|
|Lina Prasmickaite's work presented in popularised form|
|Medical imaging in cardiac research Oslo University Hospital research seminar Monday October 10th|
|Focus on personalized medicine and the MetAction study|
|Histone marks regulate maternal-to-zygotic transition Paper from Dahl/Klungland published in the Sep 22nd issue of Nature|
|Turning the tide of antimicrobial resistance National kick-off, Tuesday September 13th|
|Marina Vietri interviewed for major Italian research web portal|
|OUH researchers publish groundbreaking computer tools for cell biology research in Nature Methods|
|POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis|
|Clinical Cancer Research highlights biomarker paper from Lyngs group|
|The Norwegian Cancer Genomics Consortium participates in international study of gene variants predisposing for cancer development.|
|Annuncement of research funding from South-East Norway regional health authority for 2017 Call for applications 2017|
|H.M. the King's Gold Medal to Marina Vietri|
|Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2015|
|Atle Bjørnerud "Innovator of the Month" South-Eastern Norway Regional Health Authority brings attention to innovation:|
|Tomas Lindahl, Nobel Prize laureate 2015 Symposium at OUS, Rikshospitalet, 17. June 2016 13:00-15:30|
|The 2016 Excellent Research Awards to Pål Aukrust, Therese Seierstad and Espen Melum Oslo University Hospital honouring outstanding scientific work:|
|Strønen and Olweus publish article in Science on the use of donor immunity to target cancer|
|Håvard Danielsen and Erik Fosse receive Lighthouse project grants from the Norwegian Research Council|
|"Intelligent needle tracking using ultrasound imaging for improved minimally invasive interventions" supported by EU OUS scientists partners in project funded by HORIZON 2020 FAST TRACK TO INNOVATION|
|Discovery of biologically active small molecular compounds Oslo University Hospital research seminar Monday May 9th|
|Mapping somatic mutations in breast cancer whole genomes OUS scientists co-author Nature article:|
|Same, but different? Genetic analysis of five immune mediated diseases reveals molecular taxonomy of chronic inflammation|
|Immunotherapy for Cancer Day of Immunology Conference 2016 April 29|
|New guidelines for "Helse Sør-Øst" and "Kreftforeningen" applications Information meeting, Radiumhospitalet, Friday April 22nd|
|Ståle Nygård Dept. of Core Facilities Institute seminar April 6th|
|Article published in Science Translational Medicine showing that cyclodextrin may reduce atherosclerosis attracts worldwide attention|
|The Fridtjof Nansen Award for Young Scientists for 2016 to Kyrre Eeg Emblem|
|Theodossiou and Berg funded by the Future and Emerging Technology (FET) program|
|King Olav V's cancer research prize for 2016 to Kjetil Taskén|
|Morgendagens medisin The Norwegian Inflammation Network seminar Wednesday March 16th|
|Microbiome Oslo University Hospital research seminar Monday March 14th|
|Liliane Christ identifies mechanism for regulation of daughter cell separation|
|NoPSC study of PSC gut microbiota published in Gut|
|Olav Thon Foundation's International Prize and Research Awardees 2016 Invitation to seminar March 3rd 12:00|
|Stephen H. Friend Norsk Hydro's Fond guest lecture March 10th|
|Ragnhild A. Lothe and Michael Bretthauer substantially supported by FRIPRO|
|Filming live cancer cells Camilla Raiborg's work presented in popularised form on forskning.no:|
|Elderly patients benefit from an early invasive strategy Heart study results recently published in Lancet attract attention:|
|Lorenz et al. published an extensive study investigating the genomic chaos in osteosarcoma|
|Personalized Cancer Care Symposium, Oslo, May 18-20, 2016|
|Åslaug Hellands research on lung cancer presented by the Norwegian Cancer Society|
|Innovation projects funded by the Norwegian Cancer Society and Research Council|